中生北控生物科技股份有限公司是中国科学院和北京市政府的国有资产控股的高技术企业，以诊断产品的开发、生产和销售为主业，是目前国内最大的生化诊断试剂公司。中生北控生物科技股份有限公司的前身是北京中生生物工程高技术公司，成立于1988年，是中国科学院生物物理研究所的所办国有企业。2001年，中国科学院生物物理研究所以北京中生生物工程高技术公司整体投入发起改制，联合北京市政府在香港的窗口企业北京控股有限公司、上海市政府旗下的联创投资公司等股东投资创立并更名为中生北控生物科技股份有限公司。2006年2月27日，中生北控生物科技股份有限公司在香港联交所创业板成功上市（股票代码8247）。以此为标志，中生北控已经进入国际化、集团化、产品经营与资本经营复合化的崭新发展阶段。

公司成立以来，首创了中国“酶法诊断单、双试剂”产品系列，成功开发了肝功类、血脂类、肾功类、心肌类、特种蛋白类、微量元素类、糖代谢类等系列试剂盒70多个品种、200多个规格单、双生化试剂，诊断试剂系列产品历年均被评为北京市新技术产业开发试验区的“拳头产品”，并被列入新技术企业50强《龙虎榜》，成为我国临床诊断试剂市场公认的“国产名牌产品”。酶法诊断试剂盒系列产品技术荣获1989年中国科学院科技进步3等奖、试验区1989年优秀成果奖。1993年中生公司第一个在中国推出上机双试剂，成为国家临检中心认可的上日立全自动生化仪的公司之一。中生公司的双试剂已在日立（HITACHI）、奥林帕斯（OLYMPUS）、贝克曼（BECKMAN）等全自动生化分析仪上得到普遍使用，极大地方便了用户，很受用户欢迎。经过近二十年的发展，中生公司已经拥有了500多家代理商和销售商，拥有了该行业75%以上的用户，形成了覆盖全国的销售网络。

公司严格按照GMP标准建立新厂房，拥有国内一流的设备；采用国际先进的生产工艺和管理模式，实现微机联网和自动化联线等先进的生产工艺。2002年，公司完成了ISO9001质量体系认证。公司自创建以来一直保持了良好的持续发展势头，其经营规模逐年扩大，销售额稳定增长，成为中国科学院和北京市名列前茅的生物医药企业。

公司自主研发的酶法临床诊断试剂盒于1989年同时荣获中科院“科技进步三等奖”和北京市新技术产业开发试验区“优秀科技成果”奖。

临床诊断试剂系列从1990年以来历年均被评为北京市新技术产业开发试验区“拳头产品”。2002年，公司的体外临床诊断试剂又经北京市质量技术监督局、北京市经济委员会共同评选为“北京名牌产品”。

 
Biosino Biotechnology Company Ltd is a high-technology enterprise whose major national controlling stakeholders comprise the Chinese Academy of Sciences, Beijing Municipal Government and Shanghai Municipal Government. Through the development, production and retail of diagnostic products, Biosino has become the largest manufacturer of diagnostic biochemical assay kits in China. Formerly established in 1988 as Beijing Zhong Sheng Bio-engineering High Technology Company, it was a national enterprise under the auspices of the Chinese Academy of Sciences Institute of Biophysics. In 2001, the Chinese Academy of Sciences Institute of Biophysics backed the re-launch of the company. With investment from Chuangkou Enterprises in Hong Kong owned by Beijing Municipal Government and from Shanghai Municipal Government's Lianchuang Investment Company, together with a new name, Biosino Biotechnology Company Ltd. was established.

Since its inception, Biosino has taken the lead within China in creating a series of mono- and double- reagent diagnostic products, successfully developing a series of more than 90 assay sets directed at conditions such as hepatitis, coronary artery disease, diabetes and hyperlipidemia. Our series of over 200 standard mono- and double- reagent diagnostic tests has been consistently recognized over the years to be a leading product from the Beijing New Technology Pilot Industrial Development Zone. What is more, our enterprise has been listed as one of the top 50 "New Technology Tigers", achieving recognition for our products as a famous brand nationally.

In 1989, our series of diagnostic chemical assay kits won the Chinese Academy of Sciences' Science and Technology Award (3rd level) and the Development Zone's Outstanding Achievement Award. In 1993, Biosino became the first company in China to produce double-reagents for use in automated equipment, gaining national recognition for reagents approved for use with the Hitachi fully automated biochemical analyzer. Biosino's double-reagent products are now well established and widely used with Hitachi, Olympus, Beckman and other such analyzers, used in major centers and well-received by customers. With over a dozen years of development, Biosino's products are now promoted by over 500 agents and retailers, occupy 75% of the market and enjoy a retail network that covers the whole country.

The company has built a new factory, strictly in accordance with GMP standards, which boasts the best facilities in China. Using advanced international production technology and management models, we have achieved a microcomputer-controlled, automated biochemical technology production system. In 2002, the company passed the ISO9001 quality inspection. Ever since it was founded, the company has always maintained its healthy momentum towards continued development, annual growth and stable expansion in marketing, becoming one of the leading names in biomedical enterprise at the Chinese Academy of Sciences as well as in Beijing.

In 1989, the clinical diagnostic chemical sets developed by our company won the Chinese Academy of Sciences "Progress in Science and Technology Award" (Third Class) as well as the Beijing New Technology Pilot Industrial Development Zone "Outstanding Science and Technology Achievement Award".

Over the years since 1990, our clinical diagnostic series has consistently been found to be a leading product from Beijing's New Technology Pilot Industrial Development Zone.In 2002, the company's in vitro clinical diagnostic reagents were again reviewed by the Beijing Technology Quality Control Office and judged to be a renowned Beijing brand.